Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after hematopoietic stem cell transplantation

Transplantation

Volumn 86, Issue 5, 2008, Pages 686-696

  Nordlander, Anna ^a   Mattsson, Jonas ^a   Sundberg, Berit ^a   Sumitran Holgersson, Suchitra ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; Rejections; Stem cells

Indexed keywords

CD34 ANTIBODY; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VASCULOTROPIN RECEPTOR 2; CD34 ANTIGEN;

ADULT; AGED; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; ADOLESCENT; CHILD; DONOR; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; MIDDLE AGED; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STEM CELL;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELLS; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION IMMUNOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 53449100871     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181820333     Document Type: Article

References (31)

1. Burnett AK, Eden OB. The treatment of acute leukaemia. Lancet 1997; 349: 270.
2. MarisM, StorbR.The transplantation ofhematopoietic stem cells after non-myeloablative conditioning: A cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 2003; 28: 13.
3. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120.
4. Sumitran-Karuppan S, Tyden G, Reinholt F, et al. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997; 5: 321.
5. Nagata S, Okano S, Yonemitsu Y, et al. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice. Transplantation 2006; 82: 689.
6. Taylor PA, Ehrhardt MJ, Roforth MM, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraft-ment in allosensitized recipients. Blood 2007; 109: 1307.
7. Xu H, Chilton PM, Tanner MK, et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006; 108: 3611.
8. Bender JG, Unverzagt KL, Walker DE,et al. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 1991; 77: 2591.
9. Pelosi E, Valtieri M, Coppola S, et al. Identification of the hemangio-blast in postnatal life. Blood 2002; 100: 3203.
10. Ema M, Rossant J. Cell fate decisions in early blood vessel formation. Trends Cardiovasc Med 2003; 13: 254.
11. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954.
12. Fina L, Molgaard HV, Robertson D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417.
13. Remberger M, Svahn BM, Mattsson J, et al. Dose study of thymoglobu-lin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004; 78: 122.
14. Uzunel M, Remberger M, Sairafi D, et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006; 82: 913.
15. Remberger M, Svahn BM, Hentschke P, et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823.
16. Ringden O, Pihlstedt P, Markling L, et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7:221.
17. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390.
18. Mattsson J, Uzunel M, Tammik L, et al. Leukemia lineage-specific chi-merism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976.
19. Karuppan SS, Lindholm A, Moller E. Fewer acute rejection episodes and improved outcome in kidney-transplanted patients with selection criteria based on crossmatching. Transplantation 1992; 53: 666.
20. Warren RP, Storb R, Weiden PL, et al. Lymphocyte-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity in patients with aplastic anemia: Distinguishing transfusion-induced sensitization from possible immune-mediated aplastic anemia. Transplant Proc 1981; 13(1 Pt 1): 245.
21. Barge AJ, Johnson G, Witherspoon R, et al. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989; 74: 1477.
22. Coutinho LH, Gilleece MH, de Wynter E, et al. Clonal and long-term cultures using human bone marrow In: Testa. NG, Molineux G, eds. Haemopoiesis: A Practical Approach. Oxford, UK, Oxford 1993.
23. Eaves C, Lambie K. Atlas of human hematopoietic colonies. Vancouver, StemCell Technologies 1995.
24. Sumitran-Karuppan S, Moller E. The use of magnetic beads coated with soluble HLA class I or class II proteins in antibody screening and for specificity determinations of donor-reactive antibodies. Transplantation 1996; 61: 1539.
25. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998; 59: 313.
26. Pardanaud L, Altmann C, Kitos P, et al. Vasculogenesis in the early quail blastodisc as studied with a monoclonal antibody recognizing endothelial cells. Development 1987; 100: 339.
27. Labastie MC, Poole TJ, Peault BM, et al. MB1, a quail leukocyte-endothelium antigen: Partial characterization of the cell surface and secreted forms in cultured endothelial cells. Proc Natl Acad Sci USA 1986; 83: 9016.
28. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34( + ) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952.
29. Hristov M, Weber C. Endothelial progenitor cells: Characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8: 498.
30. Cottler-Fox MH, Lapidot T, Petit I, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003: 419.
31. Mattsson J, Ringden O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14(suppl 1): 165.